Tag Archives: Galapagos NV

Galapagos provides status update for GSK2586184

Irritable Bowel Syndrome Identifying Genetic Defect

Galapagos provides status update for GSK2586184, Galapagos NV (GLPGF) announced today that GSK has updated the development status for GSK2586184, involving three clinical studies in psoriasis, lupus, and ulcerative colitis. GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ inflammation alliance with GSK. GSK in-licensed the molecule in February 2012, gaining …